Condensed Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Revenues:
Product sales	$ 921,675	$ 543,145	$ 1,836,157	$ 1,714,340
License fee and other revenues	257,442	266,096	282,556	302,324
Research and development	144,322	89,838	330,702	284,397
Total revenues	1,323,439	899,079	2,449,415	2,301,061
Costs and Expenses:
Costs of goods sold	135,585	337,675	437,452	460,458
Research and development	12,491,290	13,298,860	39,765,180	40,473,666
Sales and marketing	302,509	248,425	703,440	778,642
General and administrative	10,514,243	1,580,824	13,969,783	4,960,959
Total costs and expenses	23,443,627	15,465,784	54,875,855	46,673,725
Operating loss	(22,120,188)	(14,566,705)	(52,426,440)	(44,372,664)
Changes in fair market value of warrant liabilities	(28,336,865)		(35,567,205)
Warrant related expenses	(7,649,395)		(7,649,395)
Interest expense	(1,369,955)	(1,369,955)	(4,109,866)	(4,109,866)
Interest and other income, net	64,574	81,911	219,536	257,631
Other financing expenses			(346,568)
Foreign currency transaction gain (loss), net	91,471	(38,699)	(117,476)	(42,210)
Loss before income tax benefit	(59,320,358)	(15,893,448)	(99,997,414)	(48,267,109)
Income tax benefit		1,871,772		5,056,772
Net loss	(59,320,358)	(14,021,676)	(99,997,414)	(43,210,337)
Less: Net loss attributable to noncontrolling interest	(14,340)	(25,631)	(46,164)	(74,420)
Net loss attributable to Immunomedics, Inc. stockholders	$ (59,306,018)	$ (13,996,045)	$ (99,951,250)	$ (43,135,917)
Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted):	$ (0.55)	$ (0.15)	$ (0.97)	$ (0.46)
Weighted average shares used to calculate loss per common share (basic and diluted)	107,839,947	94,748,252	102,756,818	94,669,326
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	$ (52,247)	$ 72,837	$ 58,569	$ 35,566
Unrealized gain (loss) on securities available for sale	5,467	90,925	(52,489)	11,658
Other comprehensive (loss) income, net of tax:	(46,780)	163,762	6,080	47,224
Comprehensive loss	(59,367,138)	(13,857,914)	(99,991,334)	(43,163,113)
Less comprehensive loss attributable to noncontrolling interest	(14,340)	(25,631)	(46,164)	(74,420)
Comprehensive loss attributable to Immunomedics, Inc. stockholders	$ (59,352,798)	$ (13,832,283)	$ (99,945,170)	$ (43,088,693)